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Abstract 
 
Introduction: Pharmaceutical expenditure rose by 16% per annum in China during the past decade, 
and now represents 46% of total health care expenditure. Initiatives to moderate growth include 
pricing regulations for pharmaceuticals and encouraging INN prescribing. However, there is limited 
monitoring of physician prescribing and current incentives encourage hospitals and physicians to 
profit from drug procurement. Objective: Assess changes in statin utilisation and expenditure as 
additional generics are launched. Subsequently, compare results in China with findings among 
European countries to provide future guidance. Methods: Observational retrospective study of statin 
utilisation and procurement expenditure from 2004 to 2013 in two large teaching hospital groups. 
Results: Statin utilisation rose 32 fold in one hospital group and 54 fold in the other. Expenditure also 
increased but to a lesser extent, i.e. from just over CNY 0.65 million in 2004 to 15.3 million in 2013 in 
one hospital group and from CNY 0.49 to 19.3 million in the other. Atorvastatin (originator) was the 
most utilised statin. Utilisation of each generic statin was typically low, e.g. 10% in 2013 in one 
hospital group. Procurement prices fell over time, greatest for generic simvastatin (-74 to -91%) 
mirroring data from European countries. However, no increase in their prescribing was observed. In 
fact, a significant decrease in generic prescribing was seen in one hospital group between 2004 and 
2013. Conclusion: There are considerable opportunities to improve prescribing efficiency in China 
based on European experience. However, current incentives encouraging hospitals and physicians to 
profit from drug procurement need to be addressed.  
 
Key words: statins; China; generics; health policies; prices; drug utilisation study 
 
Introduction 
 
There is increasing scrutiny of the growth in pharmaceutical expenditures in many countries in recent 
years. Growth rates averaging 50% in real terms during the past decade (1-3) has resulted in multiple 
reforms across countries. This growth has been driven by well-known factors including ageing 
populations and new premium priced drugs (1,2,4-6). Initiatives for new medicines include models to 
better manage the entry of new medicines to optimise the use of available resources (6-8). Initiatives 
for established medicines include measures to enhance the utilisation of low cost generics rather than 
originators and single sourced (patented) products in a single or related class where all products are 
seen as essentially similar (2,6,9-11). Examples include the proton pump inhibitors (PPIs), statins and 
renin-angiotensin system inhibiting drugs (2,6,12-20), with the latter including both angiotensin 
converting enzyme inhibitors (ACEIs) and the angiotensin receptor blockers (ARBs).  
 
 2 
 
Savings can be substantial for the medicines in these classes that are essentially therapeutically 
equivalent when the medicines are given in appropriate doses, because the prices of generics are as 
low as 2% to 10% of pre-patent loss prices in some countries (2,12,18,21-23). Multifaceted demand-
side measures enacted to achieve these savings include high International non-proprietary name 
(INN) prescribing, formularies, prescribing guidance, continuous medical education, quality circles, 
strengthening of drug and therapeutic committees (DTCs), prescribing targets, financial incentives 
and prescribing restrictions (2,12,13,18,19,21,24-26). Considerable savings can also be achieved in 
low- and middle-income countries from switching from use of originators to use of the lowest-priced 
equivalent generic drugs (27-29). 
  
China has also seen considerable increases in pharmaceutical expenditure in recent years which has 
been growing at over 16% per annum during the past decade (29-32). This has continued into the 
current decade (33). This growth has been principally driven by increasing insurance coverage (34). 
The Chinese government has introduced three different types of health insurance in recent years 
each targeting different populations, with basic coverage reaching over 90% of the population in 2011 
(33, 35-37) and 95% in 2013 (33). The ultimate goal is universal coverage by 2020 (35-40). As a 
result of increased coverage, total healthcare expenditure increased from 3.5% to 5% of GDP 
between 1995 and 2010, equating to a ten-fold increase in per capita spending from US$ 21 to 220 
(35).  Expenditure has increased more rapidly in recent years reaching US$350 per capita in 2011 
(33). In 2010, pharmaceutical revenues for Chinese public hospitals was 405.39 billion CNY 
(approximately US$ 62.4 billion), 46% of total healthcare expenditure (29,41), with out-of-pocket 
payments accounting for 36% of total healthcare expenditure (35).  
 
As a result, China has introduced a number of measures in recent years to help moderate this growth.  
These measures have principally been aimed at trying to control pharmaceutical expenditure in 
hospitals, because more than 80% of total pharmaceutical consumption in China is currently occurring 
in hospitals (29,35,37,42). For state-priced products, the National Development and Reform 
Commission (NDRC) sets maximum retail prices (price cap) including mark-ups; for province- or 
municipality-priced products, the price management department determines the retail prices. For 
other products, retail prices are determined by the manufacturers (29,35,42,43). For instance, the 
NDRC has implemented 28 price adjustments between 1997 and 2011 to address high prices for 
common or expensive medicines such as cardiovascular drugs or anticancer drugs (29,44). There 
were also eight price cuts for antibiotics between 2000 and 2005 (31).  
 
Medicines in hospitals are subject to tenders in each province and municipality with each hospital 
pharmacy deciding on its own procurement list. This has resulted in cardiovascular drug prices 
changing four times between 2006 and 2011 in Chongqing Urban District alone (29). Published 
studies have suggested these bidding processes reduced the prices of essential medicines by 16.9% 
between 2009 and 2011 (35). However, there are no formal pricing policies for generics in China 
unlike the policies introduced across Europe, which have resulted in lower price (2,4,12, 16,10,18,21, 
45). This lack of policies is at least partially responsible for the fact that there are more than 5,000 
pharmaceutical manufacturers in China producing mainly generics (29,33,42). It is expected, but not 
yet proven, that greater transparency in pharmaceutical pricing may lead to further price reductions 
(35).  
 
Demand-side measures undertaken in China include the development of an essential medicine list, 
clinical guidance and guidelines (30,33,35,46,47). However, currently there are limited measures 
being taken by public insurers to monitor the quality of prescribing (48,49). There were reforms 
introduced in 2007 - WKHµ3UHVFULSWLRQ0DQDJHPHQW2UGLQDQFH¶- specifying that prescriptions should 
be written by generic (INN) name. However, to date there has been limited enforcement (29,43). As a 
consequence, physicians tend to write prescriptions with the generic (INN) name and simultaneously 
indicate the brand or manufacturer¶V name; alternatively, they simply choose medicines listed in 
KRVSLWDOV¶information technology (IT) systems  with the corresponding brand name or manufacturer   
(29,43). This situation is not helped by having similar patient co-payments for an originator or a 
generic. In addition, in the current system, hospitals typically use the profits from medicine 
procurement for their sustainability (33,47,49).  
 
Pharmaceutical expenditure in hospitals accounted for EHWZHHQWRRIKRVSLWDOV¶WRWDO
income between 2006 and 2010 (29,33,41,43,46,48). This is because the financial support from the 
Chinese Government to public hospitals declined steadily from approximately 40% to 60% of hospital 
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revenues in 1980s, to 17% in the late 1990s and to 8.2% by 2003 (29,31). Consequently, hospitals 
use the revenue from a permitted 15% mark-up in drug procurement for their sustainability 
(29,31,33,35,43). Even after attempts to reduce procurement prices, the actual mark-up of medicines 
in hospitals in 2005 averaged approximately 42% (43). There are also inducements for physicians to 
overprescribe drugs as well as prescribe drugs that produce the greatest profit for them and the 
hospital (29,31,33,49), e.g. bonuses physicians receive directly from the manufacturers from 
prescribing their products. According to a study of 12 hospitals in Beijing from 1996 to 2005, 
expenditure on antibacterial medicines increased due to expensive antibiotics being prescribed rather 
than cheaper alternatives (31). This situation is exacerbated by the low salaries currently paid to 
physicians in China; with many physicians earning 5000 CNY (US$ 780) a month or less (50,51). This 
has resulted in considerable irrational prescribing despite the introduction of measures to decrease 
this such as essential medicine lists (29,31,33,42,43). An example of irrational prescribing is the 
continued inappropriate use of injectable drugs including injectable traditional Chinese medicines as 
well as considerable over prescribing of antibiotics including, as mentioned, the use of expensive 
versus less expensive antibiotic alternatives (31,32,49,52,53). 
 
A number of issues and findings have recently been identified (Box 1) for the use of cardiovascular 
medicines in the Chongqing Region of China (29).  
 
Box 1 ± Findings for cardiovascular medicines in the Chongqing Region in China 2006 to 2011 
 
x The market share of generics among 12 leading cardiovascular (CV) drugs decreasing from 50% 
in the first half of 2006 to 34% by the end of 2011, with the market share of originators increasing 
to 66% by the end of 2011 (based on defined daily doses) 
x The market share of originators appreciably increasing between 2006 and 2008; however, 
narrower fluctuations after this 
x Generic versions were available for all 12 CV drugs studied from 2006, with the price of 
originators averaging 63% greater than generic prices in 2011. These included 3 of the statins 
x Overall, the prices of generics for the 12 CV drugs studied varied from 0.34 to 0.98 of the 
originator in 2011, i.e. 2% to 56% price difference   
x There was potential for considerable savings with greater use of generics in this region if this 
could be engineered through additional demand side measures 
 
For a number of reasons (Box 2; references 6,12,15,17,18,20,21,25,40,52), the authors felt a study 
looking specifically at all the statins procured in China and for a longer time period was justified.  
 
Box 2 ± Rationale for studying statin utilization and expenditure  in China 
 
x Ischaemic heart disease and cerebrovascular disease are among the leading causes of death in 
China 
x Lack of appreciable therapeutic differences between the various statins or between originator and 
generic statins.  
x Published studies have shown that patients can be successfully switched between statins without 
compromising care 
x The recent expansion of the utilisation of statins with greater use in non-CV disease populations, 
e.g. patients with diabetes in addition to those with coronary vascular disease 
x The fact that some but not all previous studies in China have shown that appreciable price 
reductions are possible for generics 
x The considerable variation in demand-side measures used in Western European countries to 
encourage the preferential prescribing of low cost generic statins and the appreciable differences 
in the eventual utilisation of generic and single-sourced statins produced by these measures 
x The paucity of data on the economic effects of various measures used in China to encourage 
statin use 
x Between 2006 and 2011, some generic statins were included in hospital lists in China. As a result, 
providing an opportunity to further evaluate generic penetration rates and savings compared to 
the situation summarized in Box 1  
 
Consequently, the principal objective of this paper was to assess changes in the utilisation of and 
expenditure on statins in China when generic statins are included in procurement lists. The authors 
 4 
 
hoped to use the data generated to suggest potential future reforms that China could consider to 
enhance prescribing efficiency as China strives for universal health access such as that which exists 
in Europe. 
 
Methods 
 
Typically for these types of drug utilisation analyses, data are obtained from health authority, health 
insurance or pharmacy databases (12,14, 16, 18,19,22,23,25,54). However in China, drug utilisation 
studies are often performed with data from hospitals as they incorporate both inpatient and outpatient 
data (29,55). In addition, as mentioned, these data account for 80% of total drugs currently dispensed 
in China (29,40). This is related to the convenience of hospital dispensing which is based on 
physician recommendations. Such data also eliminates the possibility of nonstandardized community 
based prescriptions and there is greater assurance of pharmaceutical quality in hospitals (43). 
Consequently, hospital procurement data are currently an optimal source of drug utilisation data in 
China. Accurate data on hospital tendering and procurement is especially important for this type of 
analysis (43,47,49). These data are not always available from some commercial sources, which 
provide only maximum retail price data (30). Hospital procurement prices are also not always 
captured in health insurance data. In addition, hospitals may dispense medicines that are not 
currently reimbursed. As a result, health insurance data are not the optimal data source for 
comprehensive drug utilisation studies in China. 
 
&KRQJTLQJLVDPXQLFLSDOLW\GLUHFWO\XQGHU&KLQD¶VFHQWUDOJRYHUQPHQWZLWKDWRWDOSRSXODWLRQ of 28.8 
million people (2010 census). In the urban district in Chongqing City, the main public general hospitals 
include three hospitals affiliated with the Third Military Medical University (TMMU), two hospitals 
affiliated with Chongqing Medical University (CMU), and 10 municipal hospitals. Each hospital can 
dispense generic drugs from different manufacturers, but each has the same originator equivalents 
because there are only a limited number of originator manufacturers (29). 
 
We chose two teaching hospital groups in the Chongqing District to conduct our study (CMU and 
TMMU). These two hospital groups we felt to be both representative of the entire Chongqing District 
and also able to provide comprehensive datasets on both utilisation and expenditures. In view of the 
complexity of the procurement process only the largest hospitals, e.g. TMMU, tend to have a 
comprehensive range of products available for prescribing, which may influence procured prices and 
utilisation patterns. The dataset was obtained from the company publishing journals, one of which is 
named China Pharmacy The company is located in Chongqing and collects detailed information from 
large hospitals in southwest China through co-operation with public hospitals. The data contains all 
individual drug information including product names, purchase dates, dosage forms, specifications, 
manufacturers, unit prices and volumes. This is an authoritative source for drug utilisation statistics in 
China which is regularly audited. We have used a similar approach in a previous study (29). 
 
An observational, uncontrolled, retrospective study of prescriptions between 2004 and 2013 was 
performed (56). The time period includes the period of the previous study (Box 1). This methodology 
was chosen because multiple supply- and demand-side measures had been introduced during this 
period in China making it difficult to perform an interrupted time series analysis. In addition, multiple 
generic statins are available in China (Table 1) (57) and there were multiple changes to the 
procurement of statins over this period (Table 2). Both chi-square and the Fischer exact tests were 
undertaken to assess potentially significant changes in the prescribing of generics versus originators. 
 
Table 1 - Registered number of approvals for the production of generic statin preparations in China in 
January 2014 (57) 
 
Statin Registered number of approvals 
Simvastatin 156 
Rosuvastatin 13 
Pravastatin 13 
Atorvastatin 9 
Pitavastatin 6 
Fluvstatin 5 
NB Registered approvals for production of raw material drug are excluded. 
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Table 2 ± Procurement availability of statins from 2004 to 2013 
 
Statins 
TMMU hospital group CMU hospital group 
Originator Generic Originator Generic 
Simvastatin 2004 Available in 2004 2004 Available in 2004 
Pravastatin 2004 2009(June) 2004 Not available 
Fluvastatin 2004 Not available 2004 Not available 
Atorvastatin 2004 Available in 2004 2005(June) Available in 2004 
Pitavastatin 2010(July) 2012(April) Not available Not available 
Rosuvastatin 2008(Feburary) 2009(July) 2010(December) Not available 
NB: Generics may have been available in China during previous years; however, just not included in the hospital 
procurement process in view of the different choices available 
 
The Chinese currency, the 5HQPLQEL³yuan´&1<, was used to determine expenditure and 
expenditure/ DDD for statins over time. There was no allowance for inflation as we wanted to compute 
actual changes over time as a result of the tendering process. This is because most health authorities 
typically decrease prices when budgets are being exceeded (58,59) making adjustments based on 
factors such as retail price indexes or purchasing price parity difficult to justify when reviewing 
pharmaceutical prices. This is in line with previous studies (12,13,18,19, 22,23,25,54,60). We also did 
not convert CNY data to either US$ or Euros during the course of the study as we did not want the 
pricing information influenced by currency fluctuations; especially during the recent financial crises in 
Europe and the US. Originator statins are those products currently or previously possessing 
intellectual property (patent), which either come from multinational companies or are manufactured by 
joint ventures in China founded by multinational pharmaceutical companies. Generic drugs are 
domestic products produced by Chinese enterprises with local investment, including state-owned and 
private enterprises. There is strong competition between a large number of manufacturers (Table 1).  
 
Six statins were available between 2004 and 2013 in the TMMU hospital (ATC C10AA01, C10AA03, 
C10AA04, C10AA05, C10AA07, C10AA08 (61) and five statins in the CMU hospital (Table 2). 
Utilisation was measured in terms of Defined Daily Dose (DDDs); GHILQHGDVµthe average 
maintenance dose of a drug when used in its major indication in adults¶ZLWKWKLVPHDVXUHUHFRJQLVHG
as the international standard to assess utilisation patterns within and between countries (62). 2011 
DDDs were defined based on international guidance (62-64). 
 
Results 
 
Utilisation 
 
There was an appreciable increase in the prescribing of statins during the study period, increasing 32 
fold from just over 67,000 DDDs in 2004 to 2.17 million in 2013 across all products for the TMMU 
hospitals (Figure 1), and 54 fold from over 49,000 DDDs to 2.69 million for the CMU hospitals (Figure 
2). 
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Figure 1 ± Utilisation of statins (DDDs) between 2004 and 2013 in the TMMU hospitals 
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Figure 2 ± Utilisation of statins (DDDs) between 2004 and 2013 in the CMU hospitals 
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The greatest increase in utilisation was seen with atorvastain (originator and generic in the TMMU 
hospitals, and only originator in the CMU hospitals) and simvastatin, although the consumption of the 
later decreased in the most recent years (Figures 1 and 2, Table 3). The utilisation of both 
rosuvastatin and fluvastatin also increased steadily but to a lesser extent. 
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Table 3 ± Consolidated utilisation of statins (in DDDs) including generics and originators in the two 
Chongqing hospital groups from 2004 to 2013 
 
TMMU hospitals 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013
Degree of 
change
Simvastatin - Originator 15323 18133 48067 104027 209333 228800 425333 405333 360267 210933
Simvastatin - Generic 2453 560 1792 1848 9576 22008 20627 14933 7840 2240
Simvastatin - Total 17776 18693 49859 105875 218909 250808 445960 420267 368107 213173 12.0
% Genenric 13.8% 3.0% 3.6% 1.7% 4.4% 8.8% 4.6% 3.6% 2.1% 1.1%
Pravastatin - Originator 23969 27986 19291 15395 14833 11433 67200 56933 31873 58800
Pravastatin - Generic 11267 21467 22667 41327 39980
Pravastatin - Total 23969 27986 19291 15395 14833 22700 88667 79600 73200 98780 4.1
% Genenric 49.6% 24.2% 28.5% 56.5% 40.5%
Fluvastatin - Originator 15895 19623 17346 38827 34347 74667 74433 68227 175280 179200 11.3
Atorvastatin - Originator 280 2135 15631 17640 37373 145600 220080 239120 295974 665210
Atorvastatin - Generic 9282 13580 26880 29400 31353 41160 102057 215320 361491 532560
Atorvastatin - Total 9562 15715 42511 47040 68726 186760 322137 454440 657465 1197770 125.3
% Genenric 97.1% 86.4% 63.2% 62.5% 45.6% 22.0% 31.7% 47.4% 55.0% 44.5%
pitavastatin - Originator 13790 30030 42350 57330
pitavastatin - Generic 14000 10360
pitavastatin - Total 13790 30030 56350 67690
% Genenric 24.8% 15.3%
Rosuvastatin - Originator 1134 1400 15400 133497 273413 398160
Rosuvastatin - Generic 7896 1729 5600 2800 12600
Rosuvastatin - Total 1134 9296 17129 139097 276213 410760
% Genenric 84.9% 10.1% 4.0% 1.0% 3.1%
Combined total
Total Generic 11735 14140 28672 31248 40929 82331 145879 258520 427457 597740 50.9
Total Statins 67201 82018 129006 207137 337949 544231 962116 1191660 1606614 2167373 32.3
% Genenric 17.5% 17.2% 22.2% 15.1% 12.1% 15.1% 15.2% 21.7% 26.6% 27.6%
CMU hospitals 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013
Degree of 
change
Simvastatin - Originator 16053 27733 57700 95020 143060 223803 338800 505067 552533 431200
Simvastatin - Generic 11627 12333 19036 30053 46422 50003 33150 11867 7667 5950
Simvastatin - Total 27680 40066 76736 125073 189482 273807 371950 516933 560200 437150 15.8
% Genenric 42.0% 30.8% 24.8% 24.0% 24.5% 18.3% 8.9% 2.3% 1.4% 1.4%
Pravastatin - Originator 17096 14026 33250 33500 31477 18877 24383 27067 37800 30800 1.8
Fluvastatin - Originator 4247 14933 16427 23893 56929 86613 96740 146347 216907 363440 85.6
Atorvastatin - Originator 3080 21077 49980 35658 84140 140910 308140 626080 1113910
Atorvastatin - Generic 350 1820 7070 17710 33180 59640 82320 88200 172200 263760
Atorvastatin - Total 350 4900 28147 67690 68838 143780 223230 396340 798280 1377670 3936.2
% Genenric 100.0% 37.1% 25.1% 26.2% 48.2% 41.5% 36.9% 22.3% 21.6% 19.1%
Rosuvastatin - Originator 350 57890 212940 478800
Combined total
Total Generic 11977 14153 26106 47763 79602 109643 115470 100067 179867 269710 22.5
Total Statins 49373 73925 154560 250156 346725 523077 716653 1144577 1826127 2687860 54.4
% Genenric 24.3% 19.1% 16.9% 19.1% 23.0% 21.0% 16.1% 8.7% 9.8% 10.0%  
 
In January 2010, the originator manufacturer adjusted its price of simvastatin tablets 40 mg × ¶VIURP
CNY 50.30 to 26.70 in TMMU Hospitals (slightly changed to CNY 26.61 in February 2011) and its 
utilisation subsequently increased (Table 3). In September 2011 (November 2011 in CMU hospitals), 
the manufacturer changed the specification to 40 mg × ¶VDQGSULFHGDW&1<,WVXWLOL]DWLRQ
subsequently decreased in the TMMU hospitals and in 2013 in the CMU hospital. Meanwhile the 
utilisation of atorvastatin and rosuvastatin increased (Figures 1 and 2, Table 3). 
 
There was variable use of generic statins in the two hospitals. In the TMMU hospitals, there was a 
rapid increase in the use of generics. The utilisation of generic atorvastatin peaked at 97% of total 
atrovastatin in 2004 before declining to 22% in 2009, and subsequently increased to between 45% 
and 55% in recent years. A similar pattern was seen for generic pravastatin once it was procured, 
peaking at 50% of total pravastatin utilisation in 2009 before falling to 24% in 2010 and subsequently 
increasing to between 41% and 57% in recent years (Figure 1, Table 3). However, there was limited 
use of generic pitavastatin and rosuvastatin in recent years (Table 3). The variable use of generics 
among the statins led to their overall utilisation increasing from 18% of total statins in 2004 to 28% in 
2013 in the TMMU hospitals (Table 3). However, the difference in the utilisation of generic vs. 
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originator statins between 2004 and 2013 was not significant by chi-square test (p>0.05) despite the 
increasing availability of generic statins (Tables 2 and 3). 
 
In the CMU hospitals, the greatest increase was for atorvastatin (3936 fold) (Figure 2, Table 3). 
However, owing to decreasing utilisation of generic atorvastatin as a percentage of total atorvastatin, 
there was decreasing use of generic statins to 9% to 10 % of total statins in recent years (Table 3). In 
this hospital group, there was a significant difference in the utilisation of generic vs. originator statins 
between 2004 and 2013 (p<0.01 using the chi-square test). 
 
Expenditure 
 
Total expenditure on the statins increased appreciably in both hospitals, rising from just over 650,000 
CNY in 2004 to 15.3 million CNY in 2013 for the TMMU hospitals, and from 493,000 to 19.3 million 
CNY for the CMU hospitals (Figures 3 and 4). The greatest expenditure was on atorvastatin, 
amounting to 60-61% of total statin expenditure in the two hospitals (Figures 3 and 4). 
 
Figure 3 ± Total expenditure of statins in CNY in the TMMU hospitals from 2004 to 2013 
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Figure 4 - Total expenditure of statins in CNY in the CMU hospitals from 2004 to 2013 
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In the TMMU hospitals, the lower increase in total expenditure (24 fold) versus utilisation (32 fold) was 
helped by reducing expenditure/ DDD for the various statins (Table 4). There was a numerically 
smaller but statistically insignificant (p>0.05 using Fisher exact test) decrease of 23% for originator 
statins combined in 2013 vs. 2004 compared with a 38% decrease for generics. This resulted in an 
overall 27% price reduction for combined statins between 2004 and 2013 (Table 4).  
 
Table 4 ± Expenditure/ DDD for statins (generic and originator) in the two Chongqing hospitals from 
2004 to 2013 
 
Statins 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 
% change 
2013 vs. 
2004 
TMMU hospitals                       
Simvastatin - Originator 8.543  8.203  7.607  7.603  7.545  7.545  4.003  4.707  3.944  3.944  -54% 
Simvastatin - Generic 7.719  7.378  5.981  5.345  5.162  5.111  4.471  2.944  2.538  1.997  -74% 
Simvastatin % 
Difference 
-10% -10% -21% -30% -32% -32% 12% -37% -36% -49%   
Pravastatin - Originator 11.607  9.930  9.102  8.773  8.754  7.114  7.021  7.042  6.857  6.857  -41% 
Pravastatin - Generic           8.661  8.661  5.800  5.621  5.621    
Pravastatin % 
Difference 
          22% 23% -18% -18% -18%   
Fluvastatin - Originator 7.206  7.225  6.519  6.371  6.334  6.334  6.316  7.367  5.200  5.603  -22% 
Atorvastatin - Originator 15.154  15.154  10.370  9.571  9.573  9.571  9.571  9.220  8.891  8.569  -43% 
Atorvastatin - Generic 11.154  10.775  9.756  8.797  8.597  8.597  8.449  7.730  7.195  6.523  -42% 
Atorvastatin % 
Difference 
-26% -29% -6% -8% -10% -10% -12% -16% -19% -24%   
Pitavastatin - Originator             7.669  7.668  7.666  7.666    
Pitavastatin - Generic                 8.019  8.019    
Pitavastatin % 
Difference 
                5% 5%   
Rosuvastatin - 
Originator 
        7.886  7.886  7.886  7.736  7.714  7.714    
Rosuvastatin - Generic           8.606  8.606  8.205  8.071  7.267    
Rosuvastatin % 
Difference 
          9% 9% 6% 5% -6%   
Total Statins - 
Originator 
9.517  8.851  8.137  7.631  7.722  7.978  6.099  6.729  6.459  7.295  -23% 
Total Statins - Generic 10.436  10.640  9.520  8.593  7.793  7.675  7.920  7.295  6.990  6.487  -38% 
Total Statins 9.678  9.159  8.444  7.776  7.730  7.932  6.375  6.852  6.600  7.072  -27% 
CMU hospitals                       
Simvastatin - Originator 10.210  8.796  8.866  9.222  9.279  9.311  4.663  4.602  4.718  4.522  -56% 
Simvastatin - Generic 7.038  6.930  6.988  6.130  6.073  5.928  4.658  1.404  0.968  0.633  -91% 
Simvastatin % 
Difference 
-31% -21% -21% -34% -35% -36% 0% -69% -79% -86%   
Pravastatin - Originator 12.350  11.415  9.026  8.921  8.755  8.841  8.737  8.649  8.644  8.644  -30% 
Fluvastatin - Originator 7.699  6.567  6.516  6.516  6.516  6.516  6.516  6.131  6.131  4.541  -41% 
Atorvastatin - Originator   8.841  9.571  9.573  9.571  9.571  9.571  8.891  8.891  8.889    
Atorvastatin - Generic 10.463  9.858  9.714  8.703  8.597  8.597  8.597  7.811  7.356  7.049  -33% 
Atorvastatin % 
Difference 
  12% 1% -9% -10% -10% -10% -12% -17% -21%   
Rosuvastatin - 
Originator 
            8.571  7.719  7.714  7.714    
Total Statins - 
Originator 
10.903  8.856  8.723  8.940  8.668  8.757  6.279  6.359  6.969  7.221  -34% 
Total Statins - Generic 7.139  7.307  7.726  7.084  7.125  7.380  7.466  7.051  7.084  6.907  -3% 
Total Statins 9.990  8.559  8.554  8.585  8.313  8.468  6.471  6.420  6.980  7.189  -28% 
NB: % differences reflect differences in procurement prices between originators and generics 
 
In the CMU hospitals, the smaller increase in total expenditure (39 fold) versus utilisation (54 fold) 
was again helped by reducing expenditure/ DDD for the various statins (Table 4). There was a 
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numerically greater decrease for originator statins combined at 34% in 2013 vs. 2004 compared with 
only 3% for generics. However this difference also did not reach statistical significance (p>0.05 using 
Fisher exact test). These changes resulted however in an overall 28% price reduction for combined 
statins between 2004 and 2013 (Table 4).  
 
There was considerable variation in price reductions for individual generic and originator statins over 
the course of the study. The greatest price decline was observed for simvastatin. Prices of the 
originator declined by 54-56% in the two hospital groups over the course of the study, with prices for 
generic simvastatin declining even further (Table 4). 
 
Whilst the two hospital groups participate in the pharmaceutical tendering process in Chongqing 
District, the displayed expenditure/DDD of statins showed differences (Table 4). These are mainly 
attributable to the different specifications during the procurement process between the two hospitals, 
e.g. 40mg × ¶VLQ7008KRVSLWDODQGPJ × ¶V	PJ × ¶VLQ&08KRspitals for originator 
simvastatin, 20mg × ¶VLQ7008KRVSLWDODQGPJ × ¶VLQ&08KRVSLWDOVIRUJHQHULFDWRUYDVWDWLQLQ
2013. In addition, some products with different dosage forms and manufacturers were procured 
differently by the two hospital groups, e.g. capsules in the TMMU hospitals and tablets in the CMU 
hospital for generic simvastatin.  
 
Discussion 
 
There appears to be progress with obtaining reasonable price reductions for generics versus 
originators in hospitals in China. This can be seen with procurement price reductions over time for 
generic statins as well as for originator prices (Table 4). However, some prices of the generics 
appeared initially higher than originators, e.g. pravastatin, pitavastatin and rosuvastatin in the TMMU 
hospitals and atorvastatin in the CMU hospitals (Table 4). This could due to a limited price differential 
policy between the manufacturers of originator and generic drugs initially. At the first requested 
procurement opportunity, prices were self-determined by manufacturers and the whole supply chain 
prefers higher prices with higher profits. Subsequently, the products entered the medicine insurance 
list and their prices decreased either through government control or greater competition from multiple 
manufacturers. 
 
The price reductions for generics over time mirror some of those seen in Western European countries 
(2,12,18,21,54,60). However, there are still opportunities for further price reductions with generic 
simvastatin which is priced at between 2% to 4% of patented prices in the Netherlands, Sweden and 
UK for example (12,13, 18, 21). Potential initiatives could include new regulations encouraging 
greater transparency in the pricing of generics. In the UK, this resulted in the prices of generics falling 
by 32.4% in the first year of the introduction and generic simvastatin priced at just 3% of pre-patent 
loss prices in recent years (6,12,25).  
 
There continued to be irrationality in the prescribing of statins over time. This included the limited and 
variable prescribing of generic statins versus originators despite appreciably lower prices (Tables 3 
and 4). Generic utilisation reached a maximum of 27-28% of total statins between 2012 and 2013 in 
the TMMU hospital group having fallen to between 12% and 15% of total statins between 2008 and 
2010 (Table 3). However, utilisation decreased from 24% of total statins in 2004 to 10% in 2013 in the 
CMU hospitals (Table 3). Continued irrationality was also seen by the growing utilisation of 
atorvastatin versus simvastatin, and limited use of generic simvastatin (Figures 1 and 2, Table 3), with 
both seen as therapeutically similar at appropriate doses (12,15,16-18). Simvastatin originator 
(cheapest) was priced between 49% and 58% lower than atorvastatin originator (most expensive) 
between 2010 and 2013 in the TMMU hospitals (47% to 51% in the CMU hospitals), and simvastatin 
generic (cheapest) was between 68% and 77% cheaper than originator atorvastatin in the TMMU 
hospitals in recent years (84% to 93% in CMU hospitals).  
 
Overall, there appear to be considerable opportunities to enhance the utilisation of low cost generics 
versus originators, especially following recent reforms in China to improve manufacturing standards 
for generics. These new standards include strict quality control for generics as part of the tendering 
process (35,40). A number of quality control measures were introduced after 2000 in China (35). For 
instance as of 2009, all medicines on the Chinese EML are required to undergo quality sampling and 
testing at the provincial level at least annually and at the central level at least every three years to be 
considered eligible for procurement (35). Good Manufacturing Practice (GMP) standards were also 
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revised in 2011 to further improve the quality of generic manufacturing in China, adding to the 
potential trust in generics (35).  
 
However, it is likely future demand-side measures will have only limited success unless the current 
incentives encouraging physicians and hospitals to prescribe and dispense premium priced 
originators versus lower cost generics are addressed (29,31,33,53). Once these are adequately 
addressed, potential additional demand-side measures could include greater enforcement of INN 
prescribing. Voluntary INN prescribing in Scotland, achieved through a variety of demand side 
measures, including physician training in medical schools and follow-up in ambulatory care, resulted 
in INN prescribing rates of 98% to 99% of total utilisation among a range of classes and drugs (60).  
 
There are also opportunities to enhance the rational use of medicines in China, building on the 
essential medicine list concept (33,35, 49). This includes encouraging the preferential prescribing of 
low cost multiple sourced drugs versus more expensive patented products or originators, and building 
on INN prescribing. Restricting prescribing choices should enhance physician familiarity with the 
medicines they prescribe. This could potentially reduce adverse drug reactions and drug: drug 
interactions as well as strengthen the procurement process. This was the philosophy behind the 
generation of the Wise List in the Stockholm Healthcare Region, Sweden, which contains 
approximately 200 drugs including first and second line choices covering most of the needs in 
ambulatory care (21,24,65). An additional 100 drugs are included in a separate list reserved for 
common needs in specialist in- and out-patient care. High adherence rates at 80 to 90%% to the 
voluntary Wise List are enhanced by the involvement of prescribers in the selection process, a 
comprehensive communication program including a separate list for both patients and physicians, 
physician trust in the guidance, as well as regular feedback (24,65). Increased adherence also 
reduces costs (21,24,66). There are similar examples in Spain and Scotland (12,60,65). 
 
Such a system could be introduced throughout the hospitals in the Chongqing District along with 
continuous medical education and strengthening of hospital DTCs. This could provide an example to 
other provinces and municipalities throughout China as they grapple with similar issues. This will 
require strong leadership to achieve this, including instigating quality measures and involving 
prescribers (67) but the potential economic benefits are great. Restricting the formulary to just one 
statin based on the cheapest statin (simvastatin) would have saved an accumulated 27 million CNY 
for the TMMU hospitals alone between 2004 and 2013. Accumulated savings could increase to 49 
million CNY with the attainment of generic prices similar to low prices achieved in some Western 
(XURSHDQFRXQWULHV6LPYDVWDWLQLVUHFRPPHQGHGLQWKHµ:LVH/LVW¶LQ6WRFNKROP&RXQW\&RXQFLO 
(66). In addition, SIGN (Scottish Intercollegiate Guidelines Network) in Scotland  advocate the use of 
only 40 mg simvastatin for the prevention of cardiovascular disease (68,69) as well as for primary 
prevention of cardiovascular disease in patients with Type 1 diabetes. In addition, 40mg simvastatin 
or 10mg atorvastatin are used for the prevention of cardiovascular disease in patients with Type 2 
diabetes irrespective of starting lipid levels (69,70). The IDEAL study failed to show a significant 
reduction in coronary vascular events for patients prescribed high dose atorvastatin ( 80mg/ day) 
versus low dose simvastatin (20mg/ day) further endorsing the choice of generic simvastatin in such 
patients (71). However, we concede that initially it may be better to offer a choice, e.g. simvastatin 
and atorvastatin, based on current utilisation patterns and guidance. 
 
While it remains to be proven, we believe these findings are generalizable to other drug classes and 
other hospitals in China based on the merits of our methodology as well as the realities of current 
regulations and tendering systems in China. However, this is a recognised weakness of our approach. 
Never-the-less, we believe our conclusions that ongoing reforms in China are leading to price 
reductions, mirroring those seen in other countries, are justified. We also feel that there is still an 
opportunity to achieve further substantial price reductions and that there are also considerable 
opportunities to enhance the rational use of medicines, achieving further savings without 
compromising care. We believe these can be achieved through active formulary management and an 
increase in continuous physician medical education. This includes benchmarking physician 
prescribing habits similar to what has been achieved by initiatives in Scotland, Spain and Sweden 
(60,65). However, as discussed, for long term, sustained rational use of medicines in China, there 
must be changes in the remuneration system for hospitals and physicians to reduce their reliance on 
the profitability from drug procurement for their continued sustainability. This would build on current 
contracting initiatives in hospitals in other districts and settings (31,72). In addition, professionalism 
must be improved in all aspects of hospital management (73) and perhaps introducing regulations 
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and laws to reduce unethical practices. These could mirror recent regulations and laws in Europe, 
Korea and the US (6,19,74,75). When combined, these potential changes should also enhance 
patient access to essential medicines as well as reduce their co-payments without increasing costs to 
the Chinese authorities or compromising patient care. As a result, help the Chinese authorities 
achieve their long term goal of providing universal health care access. 
   
In conclusion, we believe we have demonstrated that despite recent measures there is still 
considerable irrationality in prescribing in China. There are also considerable opportunities to 
conserve resources without compromising care.  
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